Bruker Corporation’s share was trading at $32.07 as of August 5th, with trailing and forward P/E ratios at 61.67 and 13.14, respectively. The company’s second-quarter earnings were disappointing, impacted by a decline in U.S. academic and government research funding, as well as uncertainty around U.S. trade policy. NIH funding is down 15% year-to-date, affecting demand for research instruments. Despite challenges, Bruker remains a key player in advanced research.

Read more at Yahoo Finance: Bruker Corporation (BRKR): A Bull Case Theory